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Abstract  
 
Metabotropic glutamate receptors (mGluRs) are a family of G protein-coupled receptors 
activated by glutamate, the main excitatory neurotransmitter of the mammalian central 
nervous system. These receptors are considered as potential therapeutic targets in many 
neurological diseases but a better understanding of their complex molecular dynamics and of 
their role in the normal and pathological functioning of the brain is still required. 
Manipulating mGluRs with high spatial and temporal precision holds great promise for 
deciphering their physiological and pathological functions. This article reviews several 
recently developed optogenetic and photopharmacological solutions for the optical control of 
mGluRs and their applications, from the study of the molecular dynamics of receptor 
activation to the study of their roles in vivo. 
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Highlights 
 
• mGluRs can be precisely manipulated by light using photopharmacology or 
optogenetic strategies. 
• Optogenetic pharmacology targets engineered receptors, photopharmacology 
endogenous ones.  
• Optogenetic pharmacology uses photocontrolable ligands binding to genetically 
modified mGluRs. 
• Photopharmacology is based on freely diffusible photoswitchable or photoactivable 
ligands. 
• These optical approaches have proved useful for research in vitro and in vivo.  
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Introduction 
 
Glutamate is the major excitatory neurotransmitter of the mammalian central nervous 
system (CNS). It activates two categories of receptors: ionotropic and metabotropic glutamate 
receptors (iGluRs and mGluRs). While iGluRs are ligand-gated ion channels that mediate fast 
responses to glutamate, mGluRs are class C G-protein coupled receptors (GPCRs) responsible 
for slower neuromodulatory actions of glutamate.  
Eight genes encoding mGluRs have been identified in mammalian genomes. In addition, 
several mGluR splice variants have been described, most of them altering the intracellular C-
terminal tails [1]. Based on sequence homology, signal transduction and pharmacology, 
mGluRs are subdivided into 3 groups. Group-I mGluRs (mGlu1, 5) are mainly coupled to Gq 
and, as such, activate PLC and generate intracellular calcium signals. Both group-II (mGlu2, 3) 
and group-III (mGlu4, 6, 7, 8) mGluRs are mainly coupled to Gi/o and can therefore inhibit 
adenylate cyclase and regulate the activity of various ion channels [2,3]. 
The different mGluRs are widely distributed throughout the peripheral and central nervous 
system. In neurons, group I mGluRs are mostly localized at the post-synapse where they 
upregulate neuronal excitability, whereas group II and III mGluRs are mostly presynaptic 
receptors that reduce synaptic transmission. mGluRs are not only present in glutamatergic 
synapses but they have also been observed in other types of synapses, such as dopaminergic 
and GABAergic synapses. mGluRs have also been detected in astrocytes, oligodendrocytes 
and microglia (see [4] for review). In addition, mGluRs are distributed outside the CNS, for 
example in the heart, adrenal glands or lymphocytes (see [5] for review). 
mGluRs are complex allosteric machines composed of a seven transmembrane domain 
(7TMD), common to all GPCRs, connected to a large bilobate extracellular venus-flytrap 
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domain (VFT) through a short and rigid cysteine-rich domain (CRD). Moreover, mGluRs are 
constitutive dimers cross-linked by a disulfide bridge at the level of the VFT and this 
dimerization is a prerequisite for mGluRs function [6]. Glutamate binds in the cleft between 
the two lobes of the VFT. The glutamate-binding pocket is well conserved among the 
different mGluRs, making the design of subtype selective orthosteric ligands challenging, but 
several successful molecules have been described  [2]. Positive, negative and neutral allosteric 
ligands that bind in the 7TMD have also been identified. Since this binding pocket is more 
variable than that of glutamate among mGluR  subtypes, it has allowed  the discovery of 
subtype selective allosteric ligands of mGluRs [3]. Allosteric modulators targeting the VFT 
have also been described, such as cations and anions [7-12]. Moreover, mGluRs that were 
long believed to exclusively form homodimers can also assemble into heterodimers, 
multiplying the receptor combinations and their subsequent signaling and modulatory 
mechanisms [3].    
Due to their important role in the regulation of synaptic transmission and neuronal 
excitability, mGluRs are considered  potential therapeutic targets for treating neurological 
disorders, including anxiety, depression, schizophrenia, chronic pain and Parkinson disease 
(see [4,13,14] for reviews). However, despite the efforts of pharmaceutical companies, there 
are currently no marketed drugs targeting mGluRs. Drug development and clinical research 
would benefit from better knowledge of the complex molecular machinery of these receptors 
and their role in the normal and pathological functioning of the brain, including the defined 
anatomical location of receptors functionally involved in specific physiological responses.  
Therefore, the precise control over mGluR activity is crucial for a better understanding of 
their dynamics and function either in cells or in living organisms. Over the past few years, 
different optical methods have been developed to manipulate mGluRs with accurate spatial 
and temporal resolution via the use of light and photoactive molecules as external triggers for 
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receptor activation or inactivation. A first approach, optogenetic pharmacology, is based on 
covalently attached light-operated ligands while the second one, photopharmacology (also 
known as optopharmacology), is based on freely diffusible light-operated ligands. The present 
article will review the recent development of these two optical methods and their in vitro and 
in vivo applications to study mGluRs. 
 
Optogenetic pharmacology 
 
Optogenetic pharmacology is based on tethered photocontrolable ligands that bind 
covalently to genetically modified proteins [15,16]. Once attached, these ligands enable rapid, 
reversible and reproducible photoactivation or photoinactivation in specific cells expressing 
their target (Fig. 1). Before being applied to mGluRs, this approach has been used to 
photocontrol various voltage-gated and ligand-gated ion channels [15].  
Light-controlled mGluRs have been designed thanks to the joint efforts of Isacoff’s and 
Trauner’s labs. They developed a first generation of “LimGluRs” based on photoswitchable 
tethered ligands (PTLs) that contain a maleimide for cysteine attachment at one end, and  
connected via a photoisomerizable azobenzene linker to a glutamate derivative at the other 
end. These ligands, called MAGs, covalently bind to mutated mGluRs where a geometrically 
appropriate cysteine-attachment point has been incorporated. Azobenzene possesses a stable 
trans isomer and a metastable cis isomer [17]. Trans-to-cis isomerization of azobenzene can 
be induced by UV light illumination, while cis-to-trans isomerization can be induced by 
visible light or heat. Under illumination at appropriate wavelengths, azobenzene photo-
isomerization induces a change in the overall conformation of the MAG, enabling (or not) the 
interaction of the glutamate moiety with its binding pocket. Using this approach, several 
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LimGluRs have been generated: light-agonized LimGluR2, LimGluR3 and LimGluR6 and a 
light-antagonized LimGluR2 [18]. LimGluR2 has been expressed in heterologous cells, in 
rodent brain slices and in vivo in zebrafish where it controlled the function associated with 
mGlu2 receptors by light [18]. To enable a more precise spatial control of LimGluRs, some 
MAGs have been modified to enable a more accurate spatial activation by 2-Photon 
techniques [19].  
More recently, a second generation of light-controlled mGluRs has been developed using 
the SNAP-tag or CLIP-tag technology and photoswitchable orthogonal remotely tethered 
ligands (PORTL). In this method, the receptors are genetically modified to incorporate a 
SNAP-tag or a CLIP-tag at their N terminus. SNAP-tag [20] is a monomeric protein of 182 
residues (20 kDa), derived from the enzyme AGT, that recognizes and irreversibly binds to 
O6-benzylguanine (BG) derivatives. A SNAP derivative, called CLIP-tag, has been developed 
to specifically react with O4-benzylcytosine (BC) derivatives [21]. Since SNAP-tag and 
CLIP-tag possess orthogonal substrate specificities, SNAP- and CLIP-tagged proteins can be 
labeled simultaneously and specifically with different molecular probes in living cells. This 
has proven to be a highly useful and potent approach in life sciences for multiple applications 
ranging from protein detection in microscopy to the single molecule study of protein-protein 
interaction (see [22] for review). In the field of mGluRs, this technology has notably been 
used to study homodimerization [23], to discover specific heterodimeric mGluRs [24], to 
develop mGluRs biosensors [25,26] and to probe receptor activation dynamics at a single 
molecule level [27]. For optogenetic pharmacology, PORTLs have been designed to 
covalently bind to the SNAP tag or CLIP tag incorporated into the targeted receptor. They are 
composed of a glutamate moiety, followed by a long flexible linker containing an azobenzene 
and terminated with a BG or BC that specifically react with the SNAP tag or CLIP tag 
domains. This strategy has first been applied to mGlu2 permitting the photoactivation of 
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mGlu2 and the control of excitability in heterologous cells or transfected neurons [28]. Then, 
combining SNAP and CLIP tagged receptors and specific spectral variants of PORTLs, Levitz 
and colleagues have created a family of light-gated group II/III mGluRs [29], allowing 
multiplexed orthogonal optical control within receptor homo or heterodimers.  
 
Photopharmacology 
 
Photopharmacology (also called optopharmacology) is based on freely diffusible, drug-
like, light-operated ligands [30,31]. It allows the control of the function of the ligand on its 
target by light. Contrary to optogenetic pharmacology, no genetic modification of the targeted 
receptor and its exogenous expression are required, enabling the photocontrol of endogenous 
receptors. Two types of photo-regulated drugs have been developed for photopharmacology: 
photoactivable ligands and photoswitchable ligands (Fig. 1). 
 
Photoactivable ligands 
 
Photoactivable ligands are inactive ‘caged’ compounds that can be photoactivated 
following brief pulses of light. They are constituted of a ligand linked to a photo-labile 
protecting group that will be removed following illumination, enabling the uncaged ligand to 
bind to its receptor (Fig. 1). Therefore, these photoactivable ligands enable the precise control 
of the onset of drug activity at a specific location.   
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This method was developed during the seventies and first applied to nucleotides [32,33]. 
Subsequently, the caged strategy was adapted to different neurotransmitters, including 
glutamate and GABA [34,35]. Photoactivation of caged glutamate greatly improved the 
spatial and temporal resolution of synaptic connectivity mapping in neuronal networks [36]. It 
has also been used to study the function of mGluRs [37]. However, the use of caged 
glutamate is somehow limited due to the lack of subtype selectivity. This led to the 
development of iGluR and mGluR selective compounds. 
Recently, the first photoactivable ligand selective for an mGluR subtype was designed 
[38]. This caged compound called JF-NP-26 is an inactive photo-caged derivative of 
raseglurant (ADX-10059), a negative allosteric modulator (NAM) of mGlu5 receptors. 
Illumination of JF-NP-26 with violet light induces a photochemical reaction prompting the 
release of the active ligand, raseglurant, and the coumarin DEACM, and thus the blockade of 
mGlu5 receptors activity was observed in vitro in cell-based assays or in vivo in animal 
models of pain [38].  
 
Photoswitchable ligands 
 
Photoswitchable mGluRs ligands are azobenzene-containing molecules that can rapidly 
and reversibly photo-isomerize under specific light, passing from an ‘active’ to an ‘inactive’ 
configuration, or vice versa (Fig. 1). Indeed, azobenzene N=N double bond geometry changes 
during photo-isomerization [17], inducing a change in the configuration  of the ligand which 
drastically affects the affinity for its target. In the dark or under white light, the azobenzene 
moiety is in a trans configuration while it reaches the cis configuration upon illumination at 
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the adequate wavelength. Relaxation to the generally thermodynamically more stable trans-
isomer can be induced by irradiation or by spontaneous thermal relaxation.  
In the last few years, photoswitchable ligands have been developed for various ion 
channels and receptors, such as GABAA [39] and NMDA receptors [40], KATP [41], TRPA1 
[42] or GIRK channels [43], and GPCRs such as adenosine [44], µ-opioid [45] or cannabinoid 
receptors [46] among others.  
Several freely diffusible photoswitchable ligands targeting mGluRs have been developed.  
The first of them was Alloswitch-1, an mGlu5 receptor NAM [47], which was the first 
example of an allosteric photoswitchable ligand targeting a GPCR. Alloswitch-1 was 
developed based in the structure  of VU0415374, an allosteric ligand of mGlu4 receptors [48] 
in which an azobenzene was formally inserted replacing an amido group. Illumination by 
green or violet light stabilizes either the trans- or the cis-configuration of the ligand which 
correspondsto high and low pharmacological activity on mGlu5 receptors, respectively, which 
has been observed both in vitro or in vivo. Similarly, Optogluram is a photoswitchable mGlu4 
positive allosteric modulator (PAM) [49] which allows for selective, reversible and repeated 
optical manipulation of mGlu4 receptors activity with light both in vitro and in vivo. This 
ligand is also based in  VU0415374 structure but with the azobenzene formally replacing a 
different amido group  to  that used in Alloswitch-1. The enhancement of mGlu4 receptors 
activity observed by optogluram in the trans-form was reduced upon isomerization to the cis-
configuration after irradiation with violet light. The potentiation of mGlu4 receptors is 
recovered after green light Optogluram photoisomerization from cis to trans. 
As the coefficient of light absorption by tissue depends on wavelengths and ultraviolet 
light which could potentially be damaging to irradiated tissues, it is interesting to design 
ligands that can photo-isomerize at red-shifted wavelengths. Recently, OptoGluNAM4.1, a 
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blue light-sensitive mGlu4 receptors photoswitchable NAM has been described [50]. 
Interestingly, after irradiation with blue light, this compound relaxes very fast from its cis to 
trans configuration, recovering the initial configuration by simply switching-off the 
illumination thus allowing the use of a single light source. This compound is active both in 
vitro and in vivo, being able to block the action of mGlu4 receptor agonist in a light-dependent 
manner.  
More recently, a series of photoswitchable mGlu5 receptor NAMs based on the 
phenylazopyridine scaffold present in Alloswitch-1 has been generated [51]. Most of the 
trans-isomers of these ligands are active both in vitro in cell-based assays and in vivo in 
zebrafish behavioral experiments. Interestingly, depending on their structures, the ligands 
exhibit different photo-isomerization properties with, notably, optimal illumination 
wavelengths varying from 360 to 500 nm.  
 
Applications 
 
In vitro applications 
In vitro, optogenetic pharmacology and photopharmacology have great potential in allow 
us to understand how receptors function at the molecular level, how they interact with each 
other and how they modulate the activity of a given cell. They can be of particular interest to 
study all of the kinetic aspects of receptor activation and function, which are impossible to be 
address by other means [52]. 
Firstly, light-controlled mGluRs that can be rapidly and repetitively switched on and off 
by light can be useful optogenetic tools to understand the activation mechanisms of mGluRs 
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and their associated signaling. Using LimGluRs, Levitz and colleagues demonstrated the 
ability of LimGluR2 to optically modulate native downstream targets of mGlu2 receptors both 
in heterologous cells and in cultured hippocampal neurons [53]. This study also provides 
proof of concept that this strategy can be applied to study the synaptic activity of mGluRs in 
neural circuits. Indeed, the authors demonstrated that light-activation of LimGluR2 reduces 
excitability and inhibits neurotransmitter release in mouse brain slices [53]. Furthermore, the 
design of specific PTL’s compatible with 2-photon microscopy will enable high-precision 
activation of LimGluRs, making them valuable tools to map the modulation of synaptic 
activity by these receptors in neuronal networks [19]. mGluRs are complex allosteric 
machines composed of two subunits each containing different modules which interact with 
each other during the activation process. Large conformational rearrangements occur upon 
activation to transmit the information from the extracellular domains binding glutamate to the 
transmembrane domains coupling G-proteins [6]. Photoswitch has been used to probe the 
receptor dynamics during activation, demonstrating the cooperativity between the subunits of 
an mGlu2 homodimer or an mGlu2/3 heterodimer [53]. The system has been improved to 
enable dual optical control of multiple receptors using bioorthogonal tethering of PORTL 
either to SNAP or CLIP tags [28,29]. Levitz and colleagues recently achieved the independent 
photoswitch of a single or the two subunits composing an mGluR homodimer or 
heterodimers, demonstrating that these optogenetic tools can provide subunit, spatial and 
temporal precisions to the study of mGluRs dynamics and function. 
Photoswitchable and photoactivable ligands enable the optical control of endogenous 
receptors in their native environment. Photolytic release of raseglurant from its caged-
derivative JF-NP-26 effectively induces the block of the activity of heterologously expressed 
mGlu5 receptors in HEK293 cells and native ones in striatal primary neurons [38]. 
Photoswitchable allosteric modulators of mGlu5 and mGlu4 receptors reversibly 
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photoregulate the activity of their target in transfected HEK293 cells or in primary culture of 
neurons or astrocytes [47,49-51]. Contrary to optogenetic pharmacology, no genetic 
modification of the targeted receptor and its exogenous expression are required, enabling the 
photocontrol of endogenous receptors. Photoactivable ligands have been used for precise 
stimulation of receptors at defined locations in brain slices, allowing mapping of the 
distribution and function of neurotransmitter receptors in neuronal networks. Such an 
application could be feasible in principle using the photoactivable mGlu5 receptors NAM JF-
NP-26 and the photoswitchable allosteric modulators of mGlu4 and mGlu5 receptors. 
 
In vivo applications 
 
Combining optogenetic pharmacology and photopharmacology with the high spatial and 
temporal resolution of optical manipulation offers the possibility to investigate the 
physiopathological function of receptors at precise locations in living animals. However, in 
vivo optogenetic pharmacology and photopharmacology face several challenges. The first one 
concerns the genetic manipulation required by optogenetics to express the modified receptor 
to allow anchoring of the remotely tethered photoswitchable ligands in the targeted 
organisms. However, this point can be adressed by the use of viral vectors [54]. The second 
challenge resides in local ligh delivery in living organisms. Indeed, although relatively easy 
with small animal models, such as tadpoles or zebrafish, or in superficial tissues or retina, 
light delivery is more challenging in deep tissues of bigger organisms, such as rodents. 
However, thanks to the advent of optogenetics, the development of technical solutions for 
optical control is in constant progress and overcomes this obstacle.  
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The small size and transparency of Zebrafish and Xenopus tropicalis tadpoles allow easy 
and non-invasive optical manipulations in the presence of a photoresponsive molecule. 
Alloswitch-1, a photoswitchable NAM of mGlu5 receptors, allows photocontrol of the 
swimming behavior of the Xenopus tadpole [47]. Zebrafish, in particular, is a genetic model 
of choice since many years, enabling specific targeting of optogenetic tools in populations of 
cells and their subsequent monitoring by light [55]. The light-controlled mGluRs can be 
expressed in zebrafish. Photo-activation of LimGluR2 reversibly and repeatedly modulates 
the escape behavior in zebrafish [18]. Concerning photopharmacological applications, 
zebrafish also presents the interest of possessing mGluRs with high sequence homology with 
the ones of mammals [56], reducing the chances of having inactive ligands due to species 
selectivity. Notably, the allosteric binding pocket of mGlu4 receptor is well conserved 
between rodents and zebrafish [50]. Photoswitchable allosteric modulators of mGlu4 and 
mGlu5 receptors enable the photocontrol of the motility behavior of zebrafish larvae [50,51]. 
One of the striking attributes of the zebrafish model is the robustness of the translation of the 
photoswitchable properties of the ligands determined in cell-based assays with the ones 
observed in vivo, as illustrated in the study by Gomez-Santacana and colleagues [51]. In this 
structure-activity relationship study, the photopharmacological properties of a series of 
photoswitchable NAMs of mGlu5 receptors have been determined both in vitro in 
heterologous cells and in vivo in zebrafish. The optimal wavelengths of illumination range 
from 360 to 500 nm. The “photoisomerization scores” (PIS) which rank the effectiveness of 
the azobenzene photoisomerization (from poor to high) and the “photoinduced potency shifts” 
(PPS) which quantify the effectiveness of the compound photoswitching (corresponding to the 
ratio of the IC50’s under illumination and in the dark) of most of the ligands are comparable 
both in vitro and in vivo [51].  
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Using photoswitchable [49] or photoactivable mGluR drugs [38], two pioneering studies 
have recently demonstrated the feasibility of controlling endogenous neuromodulatory 
mechanisms in the brain of freely moving mice. Zussy and colleagues have injected 
optogluram, a photoswitchable PAM of mGlu4 receptors, and photocontrolled the activity of 
native mGlu4 receptors in a specific area of the brain of freely behaving mice. This study 
revealed that it is possible to regulate persistent pain-related symptoms in a temporally and 
spatially restricted manner taking control of amygdala mGlu4 receptors by light with a 
photoswitchable PAM molecule and controlling the effects at a peripheral site. To our 
knowledge, this was the first study that established that photopharmacology with a small 
diffusible drug-like photoswitchable ligand can be used in vivo to regulate the behavior in a 
disease model. Another study has demonstrated the possibility to use photoactivatable 
mGluRs ligands in vivo [38]. Font and colleagues use the caged mGlu5 receptors NAM JF-
NP-26 to control inflammatory or neuropathic pain in mice by uncaging this compound either 
at the periphery, in the paw, or centrally in the thalamus. Strikingly, this study shows that 
photoreleasing the active drug at specific locations in the brain or in the periphery results in 
analgesia, whereas targeting other mGlu5 receptors-containing tissues is devoid of any effect 
on pain sensitivity, thus linking anatomically restricted mGlu5 receptor antagonism to 
analgesic effects in vivo. 
Finally, yet importantly, there have been two recent in vivo applications of optogenetics in 
the field of mGluRs. First, using a strategy known as opto-XR [57], Van Wyk and colleagues 
designed a chimeric receptor consisting of the intracellular domains of the ON-bipolar cell–
specific mGlu6 receptor and the light-sensing domains of melanopsin that they called Opto-
mGluR6 [58]. This chimeric receptor responds to daylight by activating the GIRK signaling 
pathway in cells. Transgenic expression of opto-mGluR6 specifically in ON-bipolar cells by a 
viral approach and the GRM6/sv40 enhancer promoter restores vision in the blind rd1 mouse 
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[58]. More recently, Berry and colleagues restored vision of blind rd1 mice by transgenically 
expressing the light-activated SNAG-mGluR2 [28] in retinal ganglion cells using an AAV 
vector containing the SNAP-mGlu2 receptors under control of the synapsin promoter [59]. 
These two strategies raise hope for future therapeutic applications to restore vision. 
 
 
 
Conclusion 
 
As compared to conventional pharmacological approaches, the use of light to trigger 
receptor responses is a potent and unique tool to study their mechanisms of action, and their 
physiological and biological roles, at cellular, tissue and living animal experimental levels. In 
particular, optogenetic pharmacology and photopharmacology can greatly improve spatial and 
temporal resolution of the control over their target protein. The fundamental research tools 
presented in this review are of particular interest to study the molecular and kinetic aspects of 
mGlu receptor activation. They also hold great promise for exploring the role and therapeutic 
potential of mGluRs and their associated signaling in physiology and disease. In the near 
future, the number of available photocontrolled tools will likely increase, expanding the range 
of the current applications and helping to understand the biological particularities of the 
mGluRs extraordinary molecular machines  
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Figure 1. Different strategies to photocontrol mGluRs.  
Structural model of a dimeric mGluR composed of Venus Flytrap (VFT), Cysteine Rich 
(CRD) and a seven transmembrane domain (7TMD) domain. A first subunit is in dark grey 
while the second one is in light grey. The orthosteric binding site is located between the two 
lobes of the VFT (yellow shadow) while most allosteric modulators bind in a pocket located 
the 7TMD (blue shadow). For clarity, the orthosteric and allosteric pockets are only displayed 
in a single subunit. Optical control of mGluRs can be achevied via two main strategies. The 
optogenetic pharmacology strategy is based on photoswitchable tethered ligands binding to a 
genetically modified mGluR, harboring either a geometrically appropriate cysteine-
attachment point which will covalently bind PTL (1) or a SNAP or CLIP tag which will 
anchor PORTL (2). PTL contain a glutamate derivative at one end (orange circle) connected 
via a photoisomerizable azobenzene linker (green or purple circle) to a maleimide for cysteine 
attachment at the other end. PORTL are composed of a glutamate moiety, followed by a long 
flexible linker containing an azobenzene and terminated with a BG that will react specifically 
with the SNAP tag (or BC in case of a CLIP tag). In this figure, a PORTL is binding to its 
SNAP tag fused to the N terminus of the light grey subunit. The photopharmacology strategy 
is based on freely diffusible photoactivable (3) or photoswitchable ligands (4) that target 
endogenous mGluRs. Photoactivable ligands, also called ‘caged’ ligands, are constituted of a 
ligand linked to a photo-labile protecting group that will be removed following illumination, 
enabling the uncaged ligand to bind to its receptor. Photoswitchable mGluRs ligands are 
azobenzene-containing molecules that can rapidly and reversibly photo-isomerize under 
illumination at specific wavelenghts, passing from an ‘active’ to an ‘inactive’ configuration, 
and vice versa.  
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